Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 8/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 8/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | GLA | P06280 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2956384 | 0.80 | PDE3B (0.52) | PDE3BPDE3ALMNATNKS2CYP1A2 | |
| SCHEMBL1262197 | 0.77 | PDE3B (0.41) | PDE3BPDE3ALMNACA12CA9 | |
| SCHEMBL9860511 | 0.77 | PDE3B (0.49) | PDE3BPDE3ALMNAKDM4EALDH1A1 | |
| SCHEMBL3138208 | 0.77 | PDE3B (0.49) | PDE3BPDE3ALMNATNKS2CYP1A2 | |
| SCHEMBL22199011 | 0.76 | KDM4E (0.46) | LMNATNKS2CYP1A2CYP2C19KDM4E | |
| SCHEMBL13524439 | 0.74 | CYP19A1 (0.47) | PDE3BPDE3ALMNATNKS2CYP1A2 | |
| SCHEMBL3537387 | 0.73 | ALDH1A1 (0.49) | PDE3BPDE3ALMNATNKS2CYP1A2 | |
| SCHEMBL433885 | 0.72 | TNKS2 (0.62) | PDE3BPDE3ALMNATNKS2CYP1A2 | |
| SCHEMBL30662151 | 0.71 | ALDH1A1 (0.58) | LMNACYP1A2KDM4EALDH1A1GAA | |
| SCHEMBL833342 | 0.71 | ALDH1A1 (0.58) | LMNACYP1A2KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8435990-B2 | Dihydropyrimidone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-05-07 | — | — | US | disclosed |
| US-20110028502-A1 | DIHYDROPYRIMIDONE AMIDES AS P2X7 MODULATORS | BROTHERTON-PLEISS CHRISTINE E | 2011-02-03 | — | — | US | disclosed |
| US-7868021-B2 | Antimicrobial quinolones, their compositions and uses | WARNER CHILCOTT COMPANY, LLC (US) | 2011-01-11 | — | — | US | disclosed |
| US-7662821-B2 | improved selectivity and pharmacokinetic properties; 6-Fluoro-1-[(1 H-indazol-4-yl)amino]-4,4-dimethyl-2-(trifluoromethyl)-1,2,3,4-tetrahydronaphthalene-2,5-diol; cyclization of imines | BAYER SCHERING PHARMA AG (DE) | 2010-02-16 | — | — | US | disclosed |
| US-7659297-B2 | improved selectivity and pharmacokinetic properties; 6-Fluoro-1-[(1 H-indazol-4-yl)amino]-4,4-dimethyl-2-(trifluoromethyl)-1,2,3,4-tetrahydronaphthalene-2,5-diol; cyclization of imines | Bayer Schering Pharma, AG (DE) | 2010-02-09 | — | — | US | disclosed |
| US-7638515-B2 | improved selectivity and pharmacokinetic properties; 6-Fluoro-1-[(1 H-indazol-4-yl)amino]-4,4-dimethyl-2-(trifluoromethyl)-1,2,3,4-tetrahydronaphthalene-2,5-diol; cyclization of imines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-12-29 | — | — | US | disclosed |
| US-20090111851-A1 | Antimicrobial Quinolones, Their Compositions and Uses | WARNER CHILCOTT COMPANY, LLC | 2009-04-30 | — | — | US | disclosed |
| EP-1015445-B1 | ANTIMICROBIAL QUINOLONES, THEIR COMPOSITIONS AND USES | PROCTER & GAMBLE (US) | 2009-02-25 | — | — | EP | disclosed |
| US-7482454-B2 | Antimicrobial quinolones, their compositions, and uses | THE PROCTER & GAMBLE COMPANY (US) | 2009-01-27 | — | — | US | disclosed |
| EP-1670458-B1 | 1-AMINO-2-OXY-SUBSTITUTED TETRAHYDRONAPHTALENE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, AND THEIR USE AS ANTIPHLOGISTICS | SCHERING AG (DE) | 2006-12-20 | — | — | EP | disclosed |
| US-20030008894-A1 | Antimicrobial quinolones, their compositions and uses | THE PROCTER & GAMBLE COMPANY | 2003-01-09 | — | — | US | disclosed |
| US-20020173501-A1 | Antimicrobial quinolones, their compositions and uses | THE PROCTER & GAMBLE COMPANY | 2002-11-21 | — | — | US | disclosed |
| WO-2002048138-A1 | ANTIMICROBIAL QUINOLONES | THE PROCTER & GAMBLE COMPANY (US) | 2002-06-20 | — | — | WO | disclosed |
| WO-2002048143-A2 | ANTIMICROBIAL 2-PYRIDONES, THEIR COMPOSITIONS AND USES | THE PROCTER & GAMBLE COMPANY (US) | 2002-06-20 | — | — | WO | disclosed |
| US-6387928-B1 | BACTERICIDES; SIDE EFFECT REDUCTION | THE PROCTER & GAMBLE CO. | 2002-05-14 | — | — | US | disclosed |
| US-20020049192-A1 | Antimicrobial quinolones, their compositions and uses | THE PROCTER & GAMBLE COMPANY | 2002-04-25 | — | — | US | disclosed |
| US-6329391-B1 | ANTIBIOTICS, BACTERICIDES USING QUINOLONES | THE PROCTER & GAMBLE CO. | 2001-12-11 | — | — | US | disclosed |
| CN-1278813-A | Antimicrobial quinolones, their compositions and uses | PROCTER & GAMBLE (US) | 2001-01-03 | — | — | CN | disclosed |
| EP-1015445-A1 | ANTIMICROBIAL QUINOLONES, THEIR COMPOSITIONS AND USES | THE PROCTER & GAMBLE COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999014214-A1 | ANTIMICROBIAL QUINOLONES, THEIR COMPOSITIONS AND USES | THE PROCTER & GAMBLE COMPANY (US) | 1999-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049192-A1 | Antimicrobial quinolones, their compositions and uses | QARS1, TOP1, TOP2A | PDE3B 2048/4885PDE3A 1792/4885LMNA 1507/4885 |
| US-20090111851-A1 | Antimicrobial Quinolones, Their Compositions and Uses | QARS1, NQO2, TOP2A | PDE3B 1728/4885PDE3A 1623/4885LMNA 1461/4885 |
| US-20110028502-A1 | DIHYDROPYRIMIDONE AMIDES AS P2X7 MODULATORS | P2RY1, P2RX7, P2RX3 | PDE3B 1350/4885PDE3A 1401/4885LMNA 2432/4885 |
| US-20020173501-A1 | Antimicrobial quinolones, their compositions and uses | QARS1, TOP1, TOP2A | PDE3B 2048/4885PDE3A 1792/4885LMNA 1507/4885 |
| US-20030008894-A1 | Antimicrobial quinolones, their compositions and uses | QARS1, NQO2, Q6ZSR9 | PDE3B 1417/4885PDE3A 1310/4885LMNA 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.